ATC Group: A10BB Sulfonamides, urea derivatives

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of A10BB in the ATC hierarchy

Level Code Title
1 A Alimentary tract and metabolism
2 A10 Drugs used in diabetes
3 A10B Blood glucose lowering drugs, excl. insulins
4 A10BB Sulfonamides, urea derivatives

Group A10BB contents

Code Title
A10BB01 Glibenclamide
A10BB02 Chlorpropamide
A10BB03 Tolbutamide
A10BB04 Glibornuride
A10BB05 Tolazamide
A10BB06 Carbutamide
A10BB07 Glipizide
A10BB08 Gliquidone
A10BB09 Gliclazide
A10BB10 Metahexamide
A10BB11 Glisoxepide
A10BB12 Glimepiride
A10BB31 Acetohexamide

Active ingredients in A10BB

Active Ingredient

Chlorpropamide is a sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. It appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. The mechanism by which chlorpropamide lowers blood glucose during long-term administration has not been clearly established.

Glibenclamide, a second-generation, short half-life sulphonylurea, is a hypoglycaemic agent that reduces blood-glucose by stimulating insulin release by the pancreas. Sulphonylureas act on pancreatic beta-cells by inhibiting ATP-sensitive potassium channels.

Gliclazide is a hypoglycaemic sulfonylurea antidiabetic active substance. Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans.

Glimepiride is an orally active hypoglycaemic substance belonging to the sulphonylurea group. It may be used in non-insulin dependent (type 2) diabetes mellitus. Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.

Glipizide is an oral blood-glucose-lowering drug of the sulfonylurea class. The primary mode of action of glipizide is the stimulation of insulin secretion from the beta-cells of pancreatic islet tissue.

Gliquidone is an anti-diabetic drug in the sulfonylurea class. It is used in the treatment of diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, and eventually increases insulin release.

Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin.

Related product monographs

Document Type Information Source  
 AMARYL Tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 AMGLIDIA Oral suspension MPI, EU: SmPC European Medicines Agency (EU)
 DIABREZIDE Tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 DIAMICRON MR Modified release tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 GLIBESYN Tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 GLITISOL Tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 GLIZOREM Tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 GLUCOTROL Tablet MPI, US: SPL/Old FDA, National Drug Code (US)
 GLUCOTROL XL Extended-release tablet MPI, US: SPL/PLR FDA, National Drug Code (US)
 LAMZARIN Prolonged-release tablet MPI, EU: SmPC Health Products Regulatory Authority (IE)
 MEDOCLAZIDE Tablet MPI, EU: SmPC Υπουργείο Υγείας (CY)
 MINIDIAB Tablet MPI, EU: SmPC Pharmaceutical Benefits Scheme (AU)
 MINODIAB Tablet MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)